Will NVIDIA Stock Bounce Back?
After the wild market moves during February and March, investors…
Sell
32
NONOF Quote, Financials, Valuation and Earnings
Last price:
$65.16
Seasonality move
:
3.8%
Day range:
$65.44 - $67.67
52-week range:
$59.75 - $149.55
Dividend yield:
2.53%
P/E ratio:
20.01x
P/S ratio:
6.96x
P/B ratio:
14.56x
Volume:
673.5K
Avg. volume:
115.5K
1-year change:
-47.01%
Market cap:
$291.6B
Revenue:
$42.1B
EPS (TTM):
$3.28
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
NONOF
Novo Nordisk AS
|
$11.8B | -- | 23.74% | -- | -- |
|
ASND
Ascendis Pharma AS
|
$102.4M | -$1.65 | 252.37% | -30.12% | $216.64 |
|
GLTO
Galecto
|
-- | -$2.82 | -- | -51.46% | $8.00 |
|
GMAB
Genmab AS
|
$741.3M | $0.23 | 24.64% | -15.88% | $29.38 |
|
LLY
Eli Lilly and
|
$12.8B | $4.45 | 26.52% | 68.78% | $1,008.89 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
NONOF
Novo Nordisk AS
|
$65.68 | -- | $291.6B | 20.01x | $1.14 | 2.53% | 6.96x |
|
ASND
Ascendis Pharma AS
|
$155.50 | $216.64 | $9.3B | -- | $0.00 | 0% | 22.97x |
|
GLTO
Galecto
|
$2.49 | $8.00 | $3.3M | -- | $0.00 | 0% | -- |
|
GMAB
Genmab AS
|
$19.32 | $29.38 | $12.3B | 11.03x | $0.00 | 0% | 4.00x |
|
LLY
Eli Lilly and
|
$754.35 | $1,008.89 | $677.5B | 64.42x | $1.50 | 0.72% | 15.14x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
NONOF
Novo Nordisk AS
|
40.09% | 1.357 | 3.51% | 0.52x |
|
ASND
Ascendis Pharma AS
|
114.08% | 0.580 | 10.82% | 0.81x |
|
GLTO
Galecto
|
-- | 1.132 | -- | -- |
|
GMAB
Genmab AS
|
-- | 0.325 | -- | 5.24x |
|
LLY
Eli Lilly and
|
70.33% | 0.800 | 5.05% | 0.59x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
NONOF
Novo Nordisk AS
|
$10.4B | $5.2B | 60.28% | 86.85% | 40.78% | -$786.4M |
|
ASND
Ascendis Pharma AS
|
$170.4M | $408.3K | -69.61% | -880.05% | -24.36% | -$90.9M |
|
GLTO
Galecto
|
-- | -$7.1M | -- | -- | -- | -$4.9M |
|
GMAB
Genmab AS
|
$872.2M | $313.1M | 23.85% | 23.85% | 56.76% | $353M |
|
LLY
Eli Lilly and
|
$11.1B | $5.8B | 25.09% | 80.24% | 38.89% | $726.6M |
Novo Nordisk AS vs. Competitors
-
Which has Higher Returns NONOF or ASND?
Ascendis Pharma AS has a net margin of 32.95% compared to Novo Nordisk AS's net margin of -22.12%. Novo Nordisk AS's return on equity of 86.85% beat Ascendis Pharma AS's return on equity of -880.05%.
Company Gross Margin Earnings Per Share Invested Capital NONOFNovo Nordisk AS84.8% $0.91 $33.4B ASNDAscendis Pharma AS91.94% -$0.68 $781.4M -
What do Analysts Say About NONOF or ASND?
Novo Nordisk AS has a consensus price target of --, signalling upside risk potential of 44.93%. On the other hand Ascendis Pharma AS has an analysts' consensus of $216.64 which suggests that it could grow by 39.32%. Given that Novo Nordisk AS has higher upside potential than Ascendis Pharma AS, analysts believe Novo Nordisk AS is more attractive than Ascendis Pharma AS.
Company Buy Ratings Hold Ratings Sell Ratings NONOFNovo Nordisk AS0 0 0 ASNDAscendis Pharma AS12 1 0 -
Is NONOF or ASND More Risky?
Novo Nordisk AS has a beta of 0.646, which suggesting that the stock is 35.44% less volatile than S&P 500. In comparison Ascendis Pharma AS has a beta of 0.540, suggesting its less volatile than the S&P 500 by 45.961%.
-
Which is a Better Dividend Stock NONOF or ASND?
Novo Nordisk AS has a quarterly dividend of $1.14 per share corresponding to a yield of 2.53%. Ascendis Pharma AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk AS pays 43.71% of its earnings as a dividend. Ascendis Pharma AS pays out -- of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios NONOF or ASND?
Novo Nordisk AS quarterly revenues are $12.2B, which are larger than Ascendis Pharma AS quarterly revenues of $185.4M. Novo Nordisk AS's net income of $4B is higher than Ascendis Pharma AS's net income of -$41M. Notably, Novo Nordisk AS's price-to-earnings ratio is 20.01x while Ascendis Pharma AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk AS is 6.96x versus 22.97x for Ascendis Pharma AS. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NONOFNovo Nordisk AS6.96x 20.01x $12.2B $4B ASNDAscendis Pharma AS22.97x -- $185.4M -$41M
-
Which has Higher Returns NONOF or GLTO?
Galecto has a net margin of 32.95% compared to Novo Nordisk AS's net margin of --. Novo Nordisk AS's return on equity of 86.85% beat Galecto's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NONOFNovo Nordisk AS84.8% $0.91 $33.4B GLTOGalecto-- -$5.23 -- -
What do Analysts Say About NONOF or GLTO?
Novo Nordisk AS has a consensus price target of --, signalling upside risk potential of 44.93%. On the other hand Galecto has an analysts' consensus of $8.00 which suggests that it could grow by 221.29%. Given that Galecto has higher upside potential than Novo Nordisk AS, analysts believe Galecto is more attractive than Novo Nordisk AS.
Company Buy Ratings Hold Ratings Sell Ratings NONOFNovo Nordisk AS0 0 0 GLTOGalecto1 1 0 -
Is NONOF or GLTO More Risky?
Novo Nordisk AS has a beta of 0.646, which suggesting that the stock is 35.44% less volatile than S&P 500. In comparison Galecto has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock NONOF or GLTO?
Novo Nordisk AS has a quarterly dividend of $1.14 per share corresponding to a yield of 2.53%. Galecto offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk AS pays 43.71% of its earnings as a dividend. Galecto pays out -- of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios NONOF or GLTO?
Novo Nordisk AS quarterly revenues are $12.2B, which are larger than Galecto quarterly revenues of --. Novo Nordisk AS's net income of $4B is higher than Galecto's net income of -$6.7M. Notably, Novo Nordisk AS's price-to-earnings ratio is 20.01x while Galecto's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk AS is 6.96x versus -- for Galecto. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NONOFNovo Nordisk AS6.96x 20.01x $12.2B $4B GLTOGalecto-- -- -- -$6.7M
-
Which has Higher Returns NONOF or GMAB?
Genmab AS has a net margin of 32.95% compared to Novo Nordisk AS's net margin of 59.7%. Novo Nordisk AS's return on equity of 86.85% beat Genmab AS's return on equity of 23.85%.
Company Gross Margin Earnings Per Share Invested Capital NONOFNovo Nordisk AS84.8% $0.91 $33.4B GMABGenmab AS94.77% $0.85 $5.1B -
What do Analysts Say About NONOF or GMAB?
Novo Nordisk AS has a consensus price target of --, signalling upside risk potential of 44.93%. On the other hand Genmab AS has an analysts' consensus of $29.38 which suggests that it could grow by 52.05%. Given that Genmab AS has higher upside potential than Novo Nordisk AS, analysts believe Genmab AS is more attractive than Novo Nordisk AS.
Company Buy Ratings Hold Ratings Sell Ratings NONOFNovo Nordisk AS0 0 0 GMABGenmab AS4 4 0 -
Is NONOF or GMAB More Risky?
Novo Nordisk AS has a beta of 0.646, which suggesting that the stock is 35.44% less volatile than S&P 500. In comparison Genmab AS has a beta of 1.074, suggesting its more volatile than the S&P 500 by 7.36%.
-
Which is a Better Dividend Stock NONOF or GMAB?
Novo Nordisk AS has a quarterly dividend of $1.14 per share corresponding to a yield of 2.53%. Genmab AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk AS pays 43.71% of its earnings as a dividend. Genmab AS pays out -- of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios NONOF or GMAB?
Novo Nordisk AS quarterly revenues are $12.2B, which are larger than Genmab AS quarterly revenues of $920.3M. Novo Nordisk AS's net income of $4B is higher than Genmab AS's net income of $549.4M. Notably, Novo Nordisk AS's price-to-earnings ratio is 20.01x while Genmab AS's PE ratio is 11.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk AS is 6.96x versus 4.00x for Genmab AS. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NONOFNovo Nordisk AS6.96x 20.01x $12.2B $4B GMABGenmab AS4.00x 11.03x $920.3M $549.4M
-
Which has Higher Returns NONOF or LLY?
Eli Lilly and has a net margin of 32.95% compared to Novo Nordisk AS's net margin of 32.59%. Novo Nordisk AS's return on equity of 86.85% beat Eli Lilly and's return on equity of 80.24%.
Company Gross Margin Earnings Per Share Invested Capital NONOFNovo Nordisk AS84.8% $0.91 $33.4B LLYEli Lilly and82.24% $4.88 $47.9B -
What do Analysts Say About NONOF or LLY?
Novo Nordisk AS has a consensus price target of --, signalling upside risk potential of 44.93%. On the other hand Eli Lilly and has an analysts' consensus of $1,008.89 which suggests that it could grow by 33.74%. Given that Novo Nordisk AS has higher upside potential than Eli Lilly and, analysts believe Novo Nordisk AS is more attractive than Eli Lilly and.
Company Buy Ratings Hold Ratings Sell Ratings NONOFNovo Nordisk AS0 0 0 LLYEli Lilly and16 4 0 -
Is NONOF or LLY More Risky?
Novo Nordisk AS has a beta of 0.646, which suggesting that the stock is 35.44% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.509, suggesting its less volatile than the S&P 500 by 49.093%.
-
Which is a Better Dividend Stock NONOF or LLY?
Novo Nordisk AS has a quarterly dividend of $1.14 per share corresponding to a yield of 2.53%. Eli Lilly and offers a yield of 0.72% to investors and pays a quarterly dividend of $1.50 per share. Novo Nordisk AS pays 43.71% of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios NONOF or LLY?
Novo Nordisk AS quarterly revenues are $12.2B, which are smaller than Eli Lilly and quarterly revenues of $13.5B. Novo Nordisk AS's net income of $4B is lower than Eli Lilly and's net income of $4.4B. Notably, Novo Nordisk AS's price-to-earnings ratio is 20.01x while Eli Lilly and's PE ratio is 64.42x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk AS is 6.96x versus 15.14x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NONOFNovo Nordisk AS6.96x 20.01x $12.2B $4B LLYEli Lilly and15.14x 64.42x $13.5B $4.4B
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Energy Transfer a Good Dividend Stock to Buy Now?
Energy Transfer (NYSE:ET) offers an impressive yield, to say the…
Did the Market Bottom Already?
The past few weeks have been among the most volatile…
Stock Ideas
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
54
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 38x
Alerts
Buy
78
BMA alert for Apr 15
Banco Macro SA [BMA] is down 2.15% over the past day.
Buy
72
BKTI alert for Apr 15
BK Technologies [BKTI] is down 1.16% over the past day.
Buy
71
GGAL alert for Apr 15
Grupo Financiero Galicia SA [GGAL] is down 2.41% over the past day.
